EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Europe

Clinical biomarkers expected to lift R&D productivity: Iqvia

Drugmakers are taking longer to move a medicine from initial human testing to approval, with cumulative development times increasing from an average of about 10 year...
Continue Reading →
Europe

Biogen’s antisense ALS drug shows promise in early clinical trial

Detailed results from a phase 1 study of Biogen's anti-SOD1 ALS therapy tofersen (BIIB067) showed early promise in slowing clinical decline. (Biogen) Biogen is s...
Continue Reading →
Europe

Drugs to prevent stroke and dementia show promise in early trial

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small s...
Continue Reading →
Europe

Comprehensive tumor profiling promises new therapeutic options for patients with advanced cancer

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gu...
Continue Reading →
news

PCI Clinical Services to Showcase Expertise in Phase I Clinical Trials in Australia at East Coast, US Seminars

Philadelphia, USA – April 30, 2019 PCI Pharma Services (PCI), full-service provider of specialist outsourced drug manufacturing, clinical trial services and com...
Continue Reading →
Europe

SGS Implements Veeva Vault Clinical Trial Management System Across its Global Network

SGS, a leading life sciences, clinical and bioanalytical contract solutions provider, today announced that the company will implement the Veeva Vault CTMS (clinical...
Continue Reading →
news

Clinical Trial Supply West Coast Conference 2019: PCI’s Rich Nelson to Discuss Best Practices in the Global Movement of Scheduled Drug Product

Focusing on ‘Scheduled Drug – Processes and Complications in Global Logistics’, PCI’s Rich Nelson, Senior Manager, Global Logistics for Clinical Services, will prese...
Continue Reading →
Gaining Traction on Rare Disease Treatments
Volume 11 Issue 2

Gaining Traction on Rare Disease Treatments

While their prevalence in the United States (US) may be relatively low, ‘rare’ diseases have been garnering increasing attention in recent years through such channel...
Continue Reading →
Reimagining the Pharmaceutical Life Cycle with Artificial Intelligence
Volume 11 Issue 2

Reimagining the Pharmaceutical Life Cycle with Artificial Intelligence

From discovery to clinical trials, to marketing and managing medicinal products on the market, artificial intelligence (AI) is delivering promise and possibility to ...
Continue Reading →
After a Slow Start, US Biosimilar Approvals Accelerated in 2018
Volume 11 Issue 2

After a Slow Start, US Biosimilar Approvals Accelerated in 2018

The US Food and Drug Administration (FDA) has approved eight biosimilars since May 2018 – seven in 2018 and one more in January 2019 – nearly doubling the number app...
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18